CN104602702B - 外膜囊泡 - Google Patents

外膜囊泡 Download PDF

Info

Publication number
CN104602702B
CN104602702B CN201380045396.5A CN201380045396A CN104602702B CN 104602702 B CN104602702 B CN 104602702B CN 201380045396 A CN201380045396 A CN 201380045396A CN 104602702 B CN104602702 B CN 104602702B
Authority
CN
China
Prior art keywords
omv
protein
heterologous protein
omvs
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380045396.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104602702A (zh
Inventor
G·格兰迪
伊 若斯 I·马格里特
E·恰洛特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN104602702A publication Critical patent/CN104602702A/zh
Application granted granted Critical
Publication of CN104602702B publication Critical patent/CN104602702B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380045396.5A 2012-09-18 2013-09-18 外膜囊泡 Expired - Fee Related CN104602702B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261702296P 2012-09-18 2012-09-18
US61/702,296 2012-09-18
US201361799311P 2013-03-15 2013-03-15
US61/799,311 2013-03-15
PCT/EP2013/069415 WO2014044728A1 (en) 2012-09-18 2013-09-18 Outer membrane vesicles

Publications (2)

Publication Number Publication Date
CN104602702A CN104602702A (zh) 2015-05-06
CN104602702B true CN104602702B (zh) 2021-08-27

Family

ID=49237191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380045396.5A Expired - Fee Related CN104602702B (zh) 2012-09-18 2013-09-18 外膜囊泡

Country Status (9)

Country Link
US (1) US9764027B2 (enExample)
EP (3) EP3400960A1 (enExample)
JP (1) JP6283674B2 (enExample)
CN (1) CN104602702B (enExample)
AU (1) AU2013320313B2 (enExample)
CA (1) CA2882382A1 (enExample)
MX (1) MX363529B (enExample)
RU (1) RU2662970C2 (enExample)
WO (1) WO2014044728A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103357003A (zh) * 2006-09-07 2013-10-23 葛兰素史密丝克莱恩生物有限公司 疫苗
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
WO2015155178A1 (en) * 2014-04-07 2015-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for producing outer membrane vesicles
WO2015169773A2 (en) * 2014-05-07 2015-11-12 Glaxosmithkline Biologicals S.A. Mutants of spy0269
KR101742236B1 (ko) * 2014-10-29 2017-05-31 인하대학교 산학협력단 쯔쯔가무시병에 대한 면역 조성물 및 이의 제조방법
BR112017025954A2 (pt) 2015-06-02 2018-08-14 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport apresentação em superfície de antígenos em vesículas de membrana externa gram-negativa
CN105861402B (zh) * 2015-07-20 2020-02-14 中国医学科学院医学生物学研究所 将异源蛋白呈递于大肠杆菌外膜囊泡表面的新型疫苗形式
CN106866804B (zh) * 2015-12-11 2021-03-05 中国科学院植物研究所 一种与植物光合作用相关的cam01蛋白及其编码基因和应用
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
GB201607510D0 (en) * 2016-04-29 2016-06-15 Inst Of Food Res The Engineering gut commensal bacteria to express heterologous proteins in their outer membrane vesicles (OMV) for delivery to the GI-tract
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
MX2019006105A (es) * 2016-11-25 2019-08-21 Glaxosmithkline Biologicals Sa Conjugados de vmen-antigeno y uso de los mismos.
CN110891599A (zh) * 2017-03-31 2020-03-17 印度医学研究理事会 基于来自伤寒样沙门菌物种的两种不同菌株的外膜囊泡的肠热疫苗
US11744884B2 (en) * 2017-05-15 2023-09-05 University Of Maryland, Baltimore Live Salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
GB201708277D0 (en) * 2017-05-24 2017-07-05 Ge Healthcare A Recombinant protein
WO2019035963A1 (en) * 2017-08-16 2019-02-21 Ohio State Innovation Foundation NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
AU2019252112A1 (en) * 2018-04-10 2020-11-26 The Administrators Of The Tulane Educational Fund Burkholderia pseudomallei complex outer membrane vesicles as adjuvants
CN109554311B (zh) * 2018-12-18 2022-01-14 中国农业科学院兰州兽医研究所 一种鼠伤寒沙门氏菌外膜囊泡的提取方法
WO2020172492A2 (en) * 2019-02-22 2020-08-27 Evelo Biosciences, Inc. Bacterial membrane preparations
JP7356742B2 (ja) * 2019-04-26 2023-10-05 エムディー ヘルスケア インコーポレイテッド ストレプトコッカスパイオジェネス細菌由来タンパク質及びその用途
CN110272910A (zh) * 2019-06-25 2019-09-24 四川农业大学 一种包括jev抗原基因的重组载体、重组菌株和递呈jev抗原的外膜囊泡及其应用
US20220378902A1 (en) * 2019-08-22 2022-12-01 Sichuan University Bacterial membrane vesicles, and separation and preparation system and method therefor
KR20220130719A (ko) 2020-01-17 2022-09-27 위니베르시트카솔리끄드루뱅 엔벨로프 완전성이 변화된 유전자 변형 세균 및 이의 용도
WO2021167996A1 (en) * 2020-02-18 2021-08-26 Vaxcyte, Inc. Group a strep immunogenic compositions with polysaccharide-protein conjugates
CA3170693A1 (en) * 2020-07-30 2022-02-03 Omvax, Inc. Sars-cov-2 receptor binding domain in native outer membrane vesicles
CN117065041B (zh) * 2023-04-04 2024-02-27 山东大学 一种包被载药脂质纳米粒的外膜囊泡及其制备方法和应用
CN119932075A (zh) * 2025-01-25 2025-05-06 四川大学 一种携带外源蛋白的重组单增李斯特菌膜囊泡及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046143A2 (en) * 2004-10-29 2006-05-04 Novartis Vaccines And Diagnostics Srl Immunogenic bacterial vesicles with outer membrane proteins

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
ES2145072T3 (es) 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ES2128055T3 (es) 1994-04-20 1999-05-01 Us Army Vacuna contra infecciones de bacterias gram-negativas.
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
AU748973B2 (en) 1997-07-17 2002-06-13 Baxter Healthcare Sa Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
BR9907884A (pt) 1998-02-12 2000-10-24 American Cyanamid Co Composição de vacina, processos para gerar uma resposta imune em um antìgeno pneumocócico, para aumentar resposta de ifn-gama em uma vacina pneumocócica, e para gerar anticorpos de fixação complementar para uma resposta protetora a um patógeno, composição imunogênica, e, processo para gerar uma resposta imune em um antìgeno meningocócico
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
EP1741443B1 (en) 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
AU9475001A (en) 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2002034771A2 (en) 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
EP1423142A1 (en) 2001-08-31 2004-06-02 Chiron SRL. Helicobacter pylori vaccination with a combination of caga, vaca and nap proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
DK2255826T3 (en) 2002-08-02 2016-06-20 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens.
RU2364418C2 (ru) * 2002-08-02 2009-08-20 ГлаксоСмитКлайн Байолоджикалз с.а. ВАКЦИННЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЛИПОПОЛИСАХАРИДЫ ИММУНОТИПА L2 И/ИЛИ L3, ПРОИСХОДЯЩИЕ ИЗ ШТАММА NEISSERIA MENINGITIDIS IgtB-
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
WO2004054611A1 (en) 2002-12-16 2004-07-01 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
DE602004029657D1 (de) 2003-03-24 2010-12-02 Intercell Ag Verbesserte impfstoffe
JP4896715B2 (ja) 2003-06-26 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
EP1648500B1 (en) * 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
US7628995B2 (en) 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
UA89631C2 (en) 2004-04-05 2010-02-25 Пфайзер Продактс Инк. Vaccine composition
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
DK2682126T3 (en) * 2005-01-27 2017-02-27 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
ES2595363T3 (es) 2005-02-18 2016-12-29 J. Craig Venter Institute, Inc. Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
BRPI0609460A2 (pt) 2005-03-30 2010-04-13 Novartis Vaccines & Diagnostics Inc haemophilus influenzae tipo b
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
EP1891096A2 (en) 2005-05-12 2008-02-27 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for chlamydia trachomatis
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
EP1954306A2 (en) 2005-10-25 2008-08-13 Novartis Vaccines and Diagnostics S.r.l. Compositions comprising yersinia pestis antigens
EP2292648A3 (en) * 2006-07-07 2011-06-08 Intercell AG Small Streptococcus pyogenes antigens and their use
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
AU2007348285A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0717187D0 (en) 2007-09-04 2007-10-17 Novartis Ag Compositions comprising yersinia pestis antigens
ITMI20081249A1 (it) 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
WO2009109860A2 (en) 2008-03-06 2009-09-11 Novartis Ag Mutant forms of chlamydia htra
US9387239B2 (en) 2008-05-30 2016-07-12 U.S. Army Medical Research And Materiel Command Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
KR101042541B1 (ko) 2008-07-25 2011-06-17 한국생명공학연구원 외막소체를 생산하는 재조합 ｇ（－） 박테리아 및 이를이용한 다가항원이 실린 외막소체의 제조방법
GB0816284D0 (en) 2008-09-05 2008-10-15 Nat Biolog Standards Board Vaccine
DK2344523T3 (da) * 2008-09-17 2016-04-18 Glaxosmithkline Biolog Sa Gas-kombinationsvacciner og lægemidler
CA2758490C (en) 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
EP2493499A1 (en) * 2009-10-27 2012-09-05 Novartis AG Modified meningococcal fhbp polypeptides
WO2012020326A1 (en) * 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
GB201009861D0 (en) * 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046143A2 (en) * 2004-10-29 2006-05-04 Novartis Vaccines And Diagnostics Srl Immunogenic bacterial vesicles with outer membrane proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Immunization with Salmonella enterica serovar Typhimurium-Derived Outer Membrane Vesicles Delivering the Pneumococcal Protein PspA Confers Protection against Challenge with Streptococcus pneumoniae;Maneesha Muralinath etal;《Infection and immunity》;20101129;第79卷(第2期);第887-894页，参见摘要、第890页左栏第3段、第887页右栏最后一段、第888页左栏第1段和表1 *

Also Published As

Publication number Publication date
AU2013320313A1 (en) 2015-02-26
CN104602702A (zh) 2015-05-06
CA2882382A1 (en) 2014-03-27
WO2014044728A1 (en) 2014-03-27
RU2015106917A (ru) 2016-11-10
EP4056198A2 (en) 2022-09-14
US9764027B2 (en) 2017-09-19
JP2015535812A (ja) 2015-12-17
EP3400960A1 (en) 2018-11-14
US20150231232A1 (en) 2015-08-20
JP6283674B2 (ja) 2018-02-21
MX363529B (es) 2019-03-27
AU2013320313B2 (en) 2018-07-12
EP4056198A3 (en) 2022-12-07
RU2662970C2 (ru) 2018-07-31
EP2897635A1 (en) 2015-07-29
MX2015002484A (es) 2015-06-05

Similar Documents

Publication Publication Date Title
CN104602702B (zh) 外膜囊泡
JP7023248B2 (ja) 過剰ブレブ形成Ｓｈｉｇｅｌｌａ株
EP2890394B1 (en) Stabilised proteins for immunising against staphylococcus aureus
CN102724988B (zh) 脑膜炎球菌fHBP多肽的表达
ITMI20081249A1 (it) Immunogeni di escherichia coli con solubilità migliorata.
JP2012502073A (ja) Ｈ因子結合タンパク質免疫原
Patel et al. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines
WO2015144691A1 (en) Compositions for immunising against staphylococcus aureus
US20160067326A1 (en) Mutant bacteria for production of generalized modules for mrmbrane antigens
WO2014033192A1 (en) Stabilised proteins for immunising against staphylococcus aureus
JP2018135388A (ja) シュードモナス抗原および抗原の組み合わせ
HK40074942A (en) Outer membrane vesicles
WO2014033191A1 (en) Stabilised proteins for immunising against staphylococcus aureus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210812

Address after: Belgium Sutter Rixon

Applicant after: GLAXOSMITHKLINE BIOLOGICALS S.A.

Address before: Basel, Switzerland

Applicant before: NOVARTIS AG

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210827

CF01 Termination of patent right due to non-payment of annual fee